TW201738254A - 奧貝膽酸及其衍生物之製備方法 - Google Patents
奧貝膽酸及其衍生物之製備方法 Download PDFInfo
- Publication number
- TW201738254A TW201738254A TW106112531A TW106112531A TW201738254A TW 201738254 A TW201738254 A TW 201738254A TW 106112531 A TW106112531 A TW 106112531A TW 106112531 A TW106112531 A TW 106112531A TW 201738254 A TW201738254 A TW 201738254A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- reaction
- acid
- carried out
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662324405P | 2016-04-19 | 2016-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201738254A true TW201738254A (zh) | 2017-11-01 |
Family
ID=60116337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW106112531A TW201738254A (zh) | 2016-04-19 | 2017-04-14 | 奧貝膽酸及其衍生物之製備方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10550146B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3445370B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019515906A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180134405A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109069517A (cg-RX-API-DMAC7.html) |
| AR (1) | AR108237A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017254480A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018071441A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3021322A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2907425T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL262405A (cg-RX-API-DMAC7.html) |
| MX (1) | MX374550B (cg-RX-API-DMAC7.html) |
| TW (1) | TW201738254A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017184598A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108299539B (zh) * | 2018-03-09 | 2021-07-06 | 中山百灵生物技术股份有限公司 | 利用连续流微反应器生产6-亚乙基鹅去氧胆酸的方法 |
| CN110204587B (zh) * | 2019-07-19 | 2020-05-12 | 中山百灵生物技术有限公司 | 一种奥贝胆酸的合成方法 |
| CN113387992A (zh) * | 2020-03-11 | 2021-09-14 | 成都倍特药业股份有限公司 | 奥贝胆酸杂质及其制备方法和检测方法 |
| KR20230044603A (ko) | 2021-09-27 | 2023-04-04 | (주) 테라베스트 | 약물 이합체를 포함하는 나노입자 및 이의 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1895945A (en) * | 1928-12-20 | 1933-01-31 | Goodrich Co B F | Method of making aldehyde-amines |
| ATE303399T1 (de) | 2001-03-12 | 2005-09-15 | Intercept Pharmaceuticals Inc | Steroide als agonisten für fxr |
| EP1568706A1 (en) * | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| ITMI20050912A1 (it) * | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| EA201990211A1 (ru) | 2012-06-19 | 2019-06-28 | Интерсепт Фармасьютикалз, Инк. | Получение, применение и твердые формы обетихолевой кислоты |
| MX361653B (es) * | 2012-10-26 | 2018-12-13 | Intercept Pharmaceuticals Inc | Procedimiento para la preparación de derivados del ácido biliar. |
| CN104672290B (zh) * | 2015-01-05 | 2017-06-06 | 北京普禄德医药科技有限公司 | 一种用于预防或治疗fxr‑介导的疾病的药物及其制备方法和用途 |
| CN106046095B (zh) | 2016-06-06 | 2017-02-22 | 南京理工大学 | 奥贝胆酸的合成方法 |
-
2017
- 2017-04-14 TW TW106112531A patent/TW201738254A/zh unknown
- 2017-04-18 MX MX2018012777A patent/MX374550B/es active IP Right Grant
- 2017-04-18 AU AU2017254480A patent/AU2017254480A1/en not_active Abandoned
- 2017-04-18 CN CN201780029699.6A patent/CN109069517A/zh active Pending
- 2017-04-18 WO PCT/US2017/028130 patent/WO2017184598A1/en not_active Ceased
- 2017-04-18 KR KR1020187033097A patent/KR20180134405A/ko not_active Withdrawn
- 2017-04-18 ES ES17786465T patent/ES2907425T3/es active Active
- 2017-04-18 JP JP2018554539A patent/JP2019515906A/ja not_active Ceased
- 2017-04-18 CA CA3021322A patent/CA3021322A1/en not_active Abandoned
- 2017-04-18 US US16/094,535 patent/US10550146B2/en active Active
- 2017-04-18 BR BR112018071441A patent/BR112018071441A2/pt not_active Application Discontinuation
- 2017-04-18 EP EP17786465.9A patent/EP3445370B1/en active Active
- 2017-04-19 AR ARP170100999A patent/AR108237A1/es unknown
-
2018
- 2018-10-16 IL IL262405A patent/IL262405A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190211052A1 (en) | 2019-07-11 |
| AU2017254480A1 (en) | 2018-11-15 |
| EP3445370A1 (en) | 2019-02-27 |
| ES2907425T3 (es) | 2022-04-25 |
| EP3445370B1 (en) | 2021-12-01 |
| MX374550B (es) | 2025-03-06 |
| JP2019515906A (ja) | 2019-06-13 |
| AR108237A1 (es) | 2018-08-01 |
| IL262405A (en) | 2018-12-31 |
| BR112018071441A2 (pt) | 2019-02-05 |
| KR20180134405A (ko) | 2018-12-18 |
| EP3445370A4 (en) | 2019-12-25 |
| CN109069517A (zh) | 2018-12-21 |
| CA3021322A1 (en) | 2017-10-26 |
| WO2017184598A1 (en) | 2017-10-26 |
| MX2018012777A (es) | 2019-01-28 |
| US10550146B2 (en) | 2020-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6749406B2 (ja) | オベチコール酸およびその誘導体の調製方法 | |
| JP6830096B2 (ja) | 胆汁酸およびその誘導体の調製のための方法 | |
| TWI466671B (zh) | 末梢性類鴉片受體拮抗劑及其用途 | |
| EP3260463A1 (en) | Deuterated chenodeoxycholic acid derivative and pharmaceutical composition comprising compound thereof | |
| CA2877122A1 (en) | Preparation, uses and solid forms of obeticholic acid | |
| TW201738254A (zh) | 奧貝膽酸及其衍生物之製備方法 | |
| JP2014512399A (ja) | ナトリウム依存性グルコース輸送タンパク質阻害剤並びにその調製方法及び使用 | |
| EP3730509A1 (en) | Compound for treating metabolic diseases and preparation method and use thereof | |
| CA3070837A1 (en) | Isotopically labeled bile acid derivatives | |
| CN112142814B (zh) | 牛磺熊去氧胆酸衍生物以及包含其的药物组合物和制剂 | |
| HK1260503A1 (zh) | 制备奥贝胆酸及其衍生物的方法 | |
| CN115504972B (zh) | 异恶唑类衍生物、其制备方法及其作为药物的用途 | |
| US20220281912A1 (en) | Compounds for use in the treatment of liver disease | |
| CN120271652A (zh) | 噁二唑-甾体化合物、药物组合物和用途 | |
| JP2004323360A (ja) | 高コレステロール血症治療剤 |